Kuros Biosciences AG / Key word(s): Miscellaneous Kuros Biosciences Completes Enrollment of Randomized Stage of Phase 2 Trial for Fibrin-PTH 23.11.2022 / 07:00 CET/CEST First investigational trial of drug-biologic bone graft for spinal fusion No drug-related Serious Adverse Events (SAEs) reporte.